Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $1,021,844.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Michael Chi sold 17,102 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the sale, the insider now owns 278,654 shares of the company's stock, valued at approximately $16,649,576.50. This represents a 5.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Tuesday, June 10th, Michael Chi sold 5,600 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.00, for a total transaction of $319,200.00.
• On Friday, June 6th, Michael Chi sold 5,100 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.00, for a total transaction of $285,600.00.

Hims & Hers Health Stock Down 1.0%

Shares of NYSE HIMS traded down $0.61 during trading on Tuesday, hitting $59.17. The company had a trading volume of 35,141,346 shares, compared to its average volume of 21,323,036. The firm has a market capitalization of $13.24 billion, a price-to-earnings ratio of 139.02, a price-to-earnings-growth ratio of 2.25 and a beta of 2.09. The stock has a fifty day simple moving average of $45.77 and a two-hundred day simple moving average of $38.46. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. During the same quarter in the prior year, the firm earned $0.05 earnings per share. The company's revenue for the quarter was up 110.7% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. New York State Teachers Retirement System grew its position in Hims & Hers Health by 3,284.6% in the 4th quarter. New York State Teachers Retirement System now owns 99,812 shares of the company's stock valued at $2,413,000 after acquiring an additional 96,863 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Hims & Hers Health by 93.8% in the fourth quarter. Rhumbline Advisers now owns 516,224 shares of the company's stock valued at $12,482,000 after purchasing an additional 249,854 shares in the last quarter. Principal Securities Inc. grew its holdings in shares of Hims & Hers Health by 48.2% in the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company's stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Principal Financial Group Inc. increased its stake in Hims & Hers Health by 370.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company's stock worth $33,024,000 after buying an additional 1,075,355 shares during the period. Finally, Sanctuary Advisors LLC lifted its holdings in Hims & Hers Health by 41.4% during the 4th quarter. Sanctuary Advisors LLC now owns 36,853 shares of the company's stock worth $891,000 after buying an additional 10,796 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent research reports. Bank of America boosted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Truist Financial decreased their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Wall Street Zen raised shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $38.00.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.